Fluoride for the Treatment of Postmenopausal Osteoporotic Fractures: A Meta-Analysis

  title={Fluoride for the Treatment of Postmenopausal Osteoporotic Fractures: A Meta-Analysis},
  author={Didier Haguenauer and Vivian Andrea Welch and Beverly Shea and Peter Tugwell and Jonathan D. Adachi and George A Wells},
  journal={Osteoporosis International},
Abstract: We conducted an efectiveness meta-analysis to determine the efficacy of fluoride therapy on bone loss, vertebral and nonvertebral fractures and side effects in postmenopausal women. A literature search was conducted on MEDLINE, Current Contents and the Cochrane Controlled Trial Registry. Two independent reviewers selected randomized controlled trials which met predetermined inclusion criteria. They independently extracted data using predetermined forms and assessed the methodologic… 

Fluoride for treating postmenopausal osteoporosis.

Although fluoride has an ability to increase BMD at lumbar spine, it does not result in a reduction of vertebral fractures and in increasing the dose of fluoride, one increases the risk of non-vertebral fracture and gastrointestinal side effects without any effect on the vertebral fracture rate.

Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis

Fluoride treatment increases spine and hip BMD, depending on treatment duration, and in subgroup analyses a low fluoride dose (≤20 mg/day of fluoride equivalents) was associated with a significant reduction in fracture risk.

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

The effects of treatments on the risk of vertebral and nonvertebral fractures and on bone density, including effects in different patient subgroups are summarized and an estimate of the expected impact of antiosteoporosis interventions in prevention and treatment populations is provided using the number needed to treat (NNT) as a reference.

Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.

It is concluded that fluoride at 20 mg/d produces substantial increases in bone mineral density but still interferes with bone mineralization, indicating that much lower doses should be assessed to find a safe dose window for the use of this powerful anabolic agent.

Bone densitometry, steroids and osteoporosis.

There is increased awareness of the importance of preventive treatment for osteoporosis in patients taking high doses of oral corticosteroids, with guidelines for intervention set a higher threshold than the World Health Organization figure ( -score=-1.5 rather than -2.5) for intervention with bone sparing treatment in these patients.

Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review.

  • J. MelekA. Sakuraba
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2014

Treatment of Osteoporosis in Men with Fluoride Alone or in Combination with Bisphosphonates

An ongoing trial is studying a continuous, combined treatment of alendronate and fluoride plus calcium/vitamin D in established idiopathic osteoporosis in men, and the results of a preliminary evaluation look very promising.

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial

The combination therapy of raloxifene plus MFP favorably influences the BMD and the bone formation and resorption balance, and may reduce the risk of multiple osteoporotic fractures compared to MFP alone.